# Allogeneic Cell Therapy - Global Strategic Business Report 2026: Capitalize on 27.7% CAGR to Capture $2.4B by 2032 with Allogene, Gilead Sciences, Atara and Nkarta

- Published: 2026-11-17
- Author: [Healthcare News](https://healthcarenews.io/author/healthcarenews-io.md)
- Topics: [News](https://healthcarenews.io/news.md)
- Source: https://healthcarenews.io/news/allogeneic-cell-therapy-global-strategic-business-report-2026-capitalize-on-27-7-cagr-to-c/
- Publication: Healthcare News
- Publisher: Connectively (Terkel, Inc.)
- Editorial policy: https://healthcarenews.io/editorial-policy/

*Target scalable off-the-shelf therapies, automation, gene editing and cross-specialty applications to lower costs, accelerate access and unlock new revenue*

Dublin, Nov. 17, 2026 [(GLOBE NEWSWIRE)](https://www.globenewswire.com) -- <a href="https://www.researchandmarkets.com/reports/6070792/allogeneic-cell-therapy-global-strategic?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=dm7ffh&amp;utm_campaign=2404507+-+Allogeneic+Cell+Therapy+-+Global+Strategic+Business+Report+2026%3a+Capitalize+on+27.7%25+CAGR+to+Capture+%242.4B+by+2032+with+Allogene%2c+Gilead+Sciences%2c+Atara+and+Nkarta&amp;utm_exec=jocamsai" rel="nofollow">"Allogeneic Cell Therapy - Global Strategic Business Report 2026"</a> has been added to **ResearchAndMarkets.com's** offering.

The global allogeneic cell therapy market, valued at US$426.6 million in 2025, is projected to reach US$2.4 billion by 2032. This represents a compound annual growth rate (CAGR) of 27.7% over the forecast period. A new market research report examines the technologies, therapeutic applications, competitive dynamics, geographic opportunities and investment trends shaping this rapidly expanding segment of regenerative medicine.

**Allogeneic Cell Therapy Market Trends and Growth Drivers**

Demand for allogeneic cell therapy is increasing as healthcare systems seek scalable, readily available treatments for chronic, degenerative and life-threatening diseases. Growth is particularly strong across hematological malignancies, autoimmune disorders, cardiovascular diseases and other conditions requiring timely therapeutic intervention.

Regulatory support from agencies including the U.S. Food and Drug Administration and the European Medicines Agency continues to encourage clinical development. Accelerated review pathways, expanding clinical trial activity and growing public and private investment are supporting the advancement of promising cell-based therapies toward commercialization.

Progress in cryopreservation, cell expansion and bioprocessing is also improving product viability, consistency and shelf life. These advances are helping manufacturers address longstanding production and distribution challenges while improving the commercial feasibility of allogeneic cell therapies.

**Technology Innovation Supports Commercial Scale**

Technological developments are transforming the manufacturing, storage and delivery of allogeneic cell therapy products. CRISPR-Cas9 gene editing, induced pluripotent stem cell technology and advanced cell engineering platforms are enabling therapies with improved efficacy and lower immune-rejection risk.

Automated manufacturing systems, advanced bioreactors and standardized bioprocessing platforms are increasing production capacity while supporting consistent quality. Artificial intelligence and machine learning are also being incorporated into quality-control workflows to monitor cellular characteristics, optimize manufacturing processes and assess potential therapeutic outcomes.

Research involving 3D bioprinting is creating additional opportunities for tissue engineering and regenerative applications. Collectively, these innovations are expected to reduce production costs, strengthen safety profiles and facilitate broader clinical adoption.

**Expanding Applications Across Medical Specialties**

Although oncology and hematology remain central to the allogeneic cell therapy market, research and commercialization efforts are expanding into orthopedics, dermatology, neurology and cardiovascular medicine. Allogeneic mesenchymal stem cells are being investigated for cartilage regeneration, bone healing and osteoarthritis treatment. Dermatology applications include wound care, burn treatment, skin regeneration and selected aesthetic procedures.

Neurology represents another important area of development, with research targeting Parkinson's disease, Alzheimer's disease and spinal cord injuries. Cardiovascular programs are examining therapies for heart failure and peripheral artery disease, including approaches designed to support tissue repair and angiogenesis. Combination strategies involving immunotherapies, biomaterials and other treatment modalities are further broadening the clinical potential of allogeneic cell therapy.

**Market Segment and Regional Outlook**

-   **Stem cell therapies:** This segment is projected to reach US$1.7 billion by 2032, advancing at a CAGR of 32%.
-   **Non-stem cell therapies:** The segment is forecast to grow at a CAGR of 20.5% during the analysis period.
-   **United States:** The U.S. allogeneic cell therapy market is valued at US$116.2 million in 2025.
-   **China:** China is forecast to expand at a CAGR of 35.8%, reaching US$611.6 million by 2032.
-   **Other growth markets:** The report evaluates developments in Japan, Canada, Germany, the broader Asia-Pacific region, Europe, Latin America, the Middle East and Africa.

**Report Scope**

The report analyzes the global allogeneic cell therapy market by value in US dollars. Market segmentation includes stem cell therapies and non-stem cell therapies, as well as hematological disorders, dermatological disorders and other therapeutic areas.

Geographic coverage includes the United States, Canada, Japan, China, France, Germany, Italy, the United Kingdom, Spain, Russia, Australia, India, South Korea, Argentina, Brazil, Mexico, Iran, Israel, Saudi Arabia, the United Arab Emirates and other markets across Europe, Asia-Pacific, Latin America, the Middle East and Africa.

**Strategic Value of the Report**

-   Independent market data and annual revenue forecasts from 2025 through 2032.
-   Analysis of major market drivers, constraints, technologies and commercialization trends.
-   Regional and segment-level assessments designed to identify high-growth opportunities.
-   Competitive intelligence covering leading companies and their geographic presence.
-   Actionable insights to support investment planning, market entry and business development.
-   Complimentary report updates for one year.

**Domain Expert Insights**

The analysis incorporates perspectives from industry specialists, enterprise leaders and academic experts to provide context beyond conventional secondary research. The report tracks early market signals emerging from expert discussions, company activity, clinical programs and market-relevant developments before they are fully reflected in established datasets.

Insights are validated against conference sessions, keynote presentations, panel discussions, corporate disclosures, annual reports, institutional publications and other credible sources. This approach connects emerging signals with strategic market direction, helping decision-makers understand where growth is occurring, which technologies are gaining traction and what developments may have the greatest commercial impact.

The report also examines company-level intelligence and regional competitive structures. Rather than relying solely on a single global market share measure, it evaluates market position in major regions where competitive conditions, regulatory environments and commercialization pathways differ materially.

**Companies Featured**

Company coverage includes Adaptimmune Therapeutics plc, Allogene Therapeutics, Atara Biotherapeutics, Inc., Biosolution Co., Ltd., Gilead Sciences, Inc. (Kite), Iovance Biotherapeutics, Inc., JCR Pharmaceuticals Co., Ltd., Mallinckrodt Pharmaceuticals plc, Medipost Co., Ltd., Nkarta Therapeutics, Sumitomo Pharma Co., Ltd. and Takeda Pharmaceutical Co., Ltd.

With the global allogeneic cell therapy market forecast to expand nearly sixfold by 2032, the report provides a strategic resource for biopharmaceutical companies, investors, healthcare organizations, research institutions and other stakeholders evaluating opportunities in regenerative medicine and advanced cell therapy.

**Key Attributes**  
  

| Report Attribute | Details |
| --- | --- |
| No. of Pages | 275 |
| Forecast Period | 2025-2032 |
| Estimated Market Value (USD) in 2025 | $426.6 Million |
| Forecasted Market Value (USD) by 2032 | $2400 Million |
| Compound Annual Growth Rate | 27.7% |
| Regions Covered | Global |

  
For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6070792/allogeneic-cell-therapy-global-strategic?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=dm7ffh&amp;utm_campaign=2404507+-+Allogeneic+Cell+Therapy+-+Global+Strategic+Business+Report+2026%3a+Capitalize+on+27.7%25+CAGR+to+Capture+%242.4B+by+2032+with+Allogene%2c+Gilead+Sciences%2c+Atara+and+Nkarta&amp;utm_exec=jocamsai" rel="nofollow">https://www.researchandmarkets.com/r/782zuv</a>

**About ResearchAndMarkets.com**  
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood,Senior Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900 

  
![](https://ml.globenewswire.com/media/ZTNiZTY1NDctMDg4Yi00ZTQ4LWI2YTYtZDQ0OGM0YmQzNjQxLTEwMjY3MzctMjAyNi0xMS0xNy1lbg==/tiny/Research-and-Markets.png)

## Related

- [Cell Therapy - Global Strategic Business Report 2026-2032 | Lower Costs and Broadening Cell Therapy Applications Unlock Personalized Medicine Opportunities](https://healthcarenews.io/news/cell-therapy-global-strategic-business-report-2026-2032-lower-costs-and-broadening-cell-th.md)
- [Blue Sea Capital Closes Oversubscribed Fund IV at $800 Million](https://healthcarenews.io/news/blue-sea-capital-closes-oversubscribed-fund-iv-at-800-million.md)
- [Global Joint Replacement Devices Market Report, 2026 Edition: Forecast to 2031 | Robotic Surgery, Smart Implants, and 3D-Printed Devices Unlock Growth Opportunities](https://healthcarenews.io/news/global-joint-replacement-devices-market-report-2026-edition-forecast-to-2031-robotic-surge.md)
- [Global Diamond Bur Market Forecast and Competitive Analysis 2026-2035 | $2.1 Billion Opportunity Driven by Single-Use Burs, Cosmetic Dentistry, and APAC Growth](https://healthcarenews.io/news/global-diamond-bur-market-forecast-and-competitive-analysis-2026-2035-2-1-billion-opportun.md)
